Photo taken from Graham Collins/X
Jun 19, 2024, 07:45
Graham Collins: Starglo – A practice changing study
Graham Collins, Associate Professor of Hematology at the Oxford Cancer and Hematology Center shared a post on X:
“Starglo – EHA2024 plenary:
- R-GemOx vs. Glofit-GemOx R/R DLBCL
- 2L (SCT-ineligible) / 3L+
- OS primary EP
- Med OS 12.9 months (con) vS 25.5 months
- More TEAEs but more Rx exposure
- More deaths but mainly COVID
- G1/2 CRS as expected
A practice-changing study. ”
Source: Graham Collins/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08